A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus
References (81)
- et al.
Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
J Clin Endocrinol Metab
(1986) - et al.
Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients
Diabetologia
(2002) - et al.
Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment
Diabetes Care
(2001) - et al.
The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro
Biochem Biophys Res Commun.
(2005) - et al.
Liraglutide induces human betacell proliferation, counteracts low density lipoprotein anti-proliferative effects and protects from IL-1B induced apoptosis
Diabetes.
(2009) - et al.
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD)
Diabetes Care.
(2009) - et al.
Adding liraglutide to oral antidiabetic drug monotherapy: Efficacy and weight benefits
Postgrad Med.
(2009) - et al.
Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustments of therapy: A consensus statement of the American Diabetes Association and the European Association for Study of Diabetes
Diabetes Care
(2009) β-Cell failure in diabetes and preservation by clinical treatment
Endocr Rev
(2007)UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease [published correction appears in Diabetes. 1996;45:1655]
Diabetes
(1995)
Reduced insulin secretion/insulin resistance (disposition) index is the primary determinant of glucose intolerance in the prediabetic state: Results from ACT NOW
Diabetes Care
Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes
Acta Endocrinol (Copenh)
Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function
Diabetes Care
The importance of beta-cell management in type 2 diabetes
Int J Clin Pract Suppl
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352:1558]
Lancet
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [published correction appears in N Engl J Med. 2007;29:356]
N Engl J Med
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
BMJ
Effects of intensive glucose lowering in type 2 diabetes
N Engl J Med
Trends in A1c concentrations among US adults with diagnosed diabetes from 1999 to 2004
Diabetes Care
The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
Diabetes Care
Medication taking and diabetes: A systematic review of the literature
Diabetes Educ
Medication taking and diabetes: A systematic review of the literature
Diabetes Educ
Duration of obesity is a risk factor for non-insulin-dependent diabetes mellitus, not for arterial hypertension or for hyperlipidaemia
Acta Diabetol
Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: Findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study
Diabetes Obes Metab
Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents
Diabet Med
Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: UK Prospective Diabetes Study (UKPDS 55)
Diabetes Care
The Bedford survey: Ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics
Diabetologia
Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)
BMJ
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial
Lancet
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
Diabetologia
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
Diabetes
Determinants of the impaired secretion of glucagonlike peptide-1 in type 2 diabetic patients
J Clin Endocrinol Metab
Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells
Endocrinology
Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats
J Clin Invest
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetes rats
Endocrinology
Glucagon-like peptide-1 pre- vents beta cell glucolipotoxicity
Diabetologia
Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets
Endocrinology
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study
Lancet
Normalization of fasting hyperglycaemia by exogenous glucagonlike peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
Diabetologia
Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
Diabetologia
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects
J Clin Endocrinol Metab
Cited by (102)
Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review
2021, Diabetes and Metabolic Syndrome: Clinical Research and ReviewsCitation Excerpt :Bizino et al. (2019) also found similar results on their study [16]. This weight loss effect from GLP-1 RA also demonstrated by other studies [23–25]. Better results were found in exenatide therapy, that significantly reduced body weight, waist circumference, and total body and fat truncal fat mass [26].
GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice
2018, Biochemical and Biophysical Research CommunicationsCitation Excerpt :To overcome this, the DPP-4 inhibitors and DPP-4 resistant long-acting GLP-1 receptor agonists (GLP-1RAs) have been developed and used worldwide to treat type 2 diabetes and obesity. Recent clinical trials in type 2 diabetic patients have shown that administration of GLP-1RAs is associated with substantial reductions in glycemia, weight, systolic blood pressure (SBP) and cardiovascular events, while with low risk of hypoglycemia [8–11]. Evidence in rodents also suggests that peripheral GLP-1RAs act as trophic agents in the pancreatic β-cell proliferation and neogenesis [5,12].
Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov
2023, Journal of Multidisciplinary HealthcareTirzepatide: A New Generation Therapeutic for Diabetes Type 2
2023, Endocrine, Metabolic and Immune Disorders - Drug Targets